Mimedx (MDXG) Operating Income Growth (1y) (2012 - 2026)
Mimedx (MDXG) Operating Income Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - | -24.89% |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn | 2,150.96% |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn | 80.62% |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn | 8.65% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | 145.20% |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | 1,386.07% |
| 10 | Mimedx | 643.51 Mn | 483.74 Mn | 41.62 Mn | -294.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -294.51% |
| Dec 31, 2025 | 90.67% |
| Sep 30, 2025 | 98.80% |
| Jun 30, 2025 | -47.25% |
| Mar 31, 2025 | -37.48% |
| Dec 31, 2024 | -28.64% |
| Sep 30, 2024 | 0.34% |
| Jun 30, 2024 | 116.35% |
| Mar 31, 2024 | 3,981.76% |
| Dec 31, 2023 | 36.95% |
| Sep 30, 2023 | 256.61% |
| Jun 30, 2023 | 212.48% |
| Mar 31, 2023 | 96.34% |
| Dec 31, 2022 | 780.23% |
| Sep 30, 2022 | -560.74% |
| Jun 30, 2022 | -2,250.24% |
| Mar 31, 2022 | -35.73% |
| Dec 31, 2021 | 107.99% |
| Sep 30, 2021 | 88.93% |
| Jun 30, 2021 | 93.00% |